Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

RBMS1

Drug and asset intelligence for RBMS1 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
1
Stage
Development stage unavailable

Sponsor company

Bristol Myers Squibb →

Recent signals(1)

ClinicalJune 20, 2026

RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization

RBMS1 enhances PDPK1 mRNA stability, promoting multiple myeloma cell proliferation and M2 macrophage polarization.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Bristol Myers Squibb — RBMS1

Monitor further studies on RBMS1's role in multiple myeloma and potential therapeutic interventions targeting the RBMS1/PDPK1/β-catenin axis.

June 20, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Multiple Myeloma →
Oncology →
Oncology · Multiple Myeloma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.